Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002025811 | SCV002288880 | uncertain significance | Hyper-IgM syndrome type 1 | 2021-04-16 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Met36 amino acid residue in CD40LG. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7679206, 15358621). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CD40LG protein function. This variant has been observed in individual(s) with hyper IgM syndrome (PMID: 28916186). This variant is not present in population databases (ExAC no frequency). This sequence change replaces methionine with threonine at codon 36 of the CD40LG protein (p.Met36Thr). The methionine residue is moderately conserved and there is a moderate physicochemical difference between methionine and threonine. |